Travere Therapeutics Inc (NAS:TVTX)
$ 6.16 -0.18 (-2.84%) Market Cap: 468.95 Mil Enterprise Value: 431.93 Mil PE Ratio: 0 PB Ratio: 6.33 GF Score: 54/100

Travere Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript

May 11, 2021 / 09:00PM GMT
Release Date Price: $19.83 (+0.30%)
Gregory Allen Harrison
BofA Securities, Research Division - Research Analyst

Hi, everyone. Welcome to the Virtual Vegas Bank of America Health Care Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And it's my pleasure today to welcome Eric Dube, CEO of Travere Therapeutics.

Eric, if you'd like to make any opening remarks, please go ahead, and then we can jump into Q&A.

Eric M. Dube
Travere Therapeutics, Inc. - President, CEO & Director

Great, Greg, and thanks so much for hosting me today. As we are now in May, we had a strong start to the year. And as we look to the future and keep that end in mind that we're working towards, we really aim to bring one of the first treatments for FSGS and IgAN to the many patients who are waiting

(technical difficulty)

for these diseases. In the meantime, we're encouraged by the interim DUPLEX results in FSGS, and we're in the process of engaging with regulators about the submission for this indication.

We're also on track to report interim results from

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot